Phaseline

Companies › Acer Therapeutics

Acer Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Celiprolol (ACER-002)
Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist
ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1Phase 3Vascular Ehlers-Danlos SyndromeMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05432466Celiprolol (ACER-002)Phase 3Vascular Ehlers-Danlos SyndromeOtherMar 2029

From the company's SEC filings

Complete response letters from FDA

Targets

ADRB2 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) ADRB1 (1)

Companies with the same targets

ARS Pharmaceuticals Chiesi Farmaceutici AstraZeneca Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Tarian Pharma Alcon Research Actimed Therapeutics GSK

Companies built like this

Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma Vertanical NTC srl

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.